Anuj Agarwala
Medical Oncology · Indianapolis, INNPI 1225236201
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by AstraZeneca at 28.3% of the total. Reporting peaked in 2019 at $2,511 and has fallen 74.5% since, to $641 in 2025.
Across 193 payments — averaging $39.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Eli Lilly$2K
- Lilly USA, LLC$654
- Novartis$421
- Genentech USA, Inc.$313
- E.r. Squibb & Sons, L.L.C.$304
- plus $2K from 30 others
What the payments were for
- Consulting fees$4,44359%
- Food & beverage$2,98739%
- Education$1442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $2,146 |
| Eli Lilly | 1 | $1,875 |
| Lilly USA, LLC | 3 | $654 |
| Novartis | 26 | $421 |
| Genentech USA, Inc. | 21 | $313 |
| E.r. Squibb & Sons, L.L.C. | 18 | $304 |
| Johnson & Johnson(2 entities) | 14 | $248 |
| Pfizer | 22 | $239 |
| Merck | 12 | $180 |
| Gilead(2 entities) | 3 | $147 |
| Amgen | 9 | $122 |
| Bristol Myers Squibb | 7 | $109 |
| AVEO Pharmaceuticals, Inc. | 1 | $100 |
| AbbVie | 2 | $75 |
| Sanofi | 4 | $73 |
| EMD Serono, Inc. | 5 | $71 |
| Eisai Inc. | 5 | $67 |
| Boehringer Ingelheim | 3 | $60 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $59 |
| Exelixis Inc. | 3 | $37 |
| Astellas Pharma US Inc | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Aurobindo Pharma USA, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Verastem, Inc. | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $15 |
| Sirtex Medical Inc | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| BTG International Inc. | 1 | $12 |
| Pharmaessentia USA Corporation | 1 | $12 |
| Secura Bio, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$1,943
How this compares
$7,573 in reported general payments places this provider in the 65th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 14 | $165,515 |
| EliquisApixaban | 67 | $84,428 |
| Exemestane | 46 | $17,607 |
| Anastrozole | 333 | $6,484 |
| Ondansetron Hcl | 85 | $3,204 |
| Tamoxifen Citrate | 62 | $1,640 |
| Prochlorperazine Maleate | 108 | $1,205 |
| Potassium Chloride | 35 | $622 |
| Gabapentin | 27 | $456 |
| Warfarin Sodium | 45 | $403 |
| Dexamethasone | 69 | $378 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 21 | $300 |
| Alendronate Sodium | 56 | $261 |
| Omeprazole | 27 | $219 |
| LoperamideLoperamide Hcl | 19 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $29 | $165,51514 claims |
| PfizerEliquis | $239 | $84,42867 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $26 | $7811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Indianapolis
- Natraj AmmakkanavarIndianapolis$129K
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
- Daniel SonnenburgIndianapolis$37K
- Sumeet BhatiaIndianapolis$24K
- Michael SlaughterIndianapolis$17K
- Elsayed AlyIndianapolis$9K
- Sead BeganovicIndianapolis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.